Answers are grounded in this paper and cite their sources.
Develops niosome-encapsulated sunscreen improving vitiligo treatment and UV protection.
Background: The current study aimed to develop and assess clobetasol propionate-loaded niosomes-based sunscreen for topical vitiligo treatment. Vitiligo is an autoimmune disease characterized by melanocyte loss and the development of white patches in affected areas. Topical administration of clobetasol propionate, a glucocorticoid class steroid, treats vitiligo and other skin conditions. Because the systemic distribution of clobetasol propionate has several negative effects, including adrenal gland problems, high blood sugar, eyesight issues, and long-term use leads to skin thinning and stretch marks, to overcome these problems, topical treatment is preferable. Since vitiligo patients' skin is intolerant and more vulnerable to sunburn and skin cancer because they lack melanocytes that shield the skin from UV damage, sunscreen is the most effective strategy to protect their skin from damaging UV rays while lowering their risk of developing skin cancer. Objective: The study aimed to create a topical sunscreen using niosomes loaded with clobetasol propionate. Creating this sunscreen to treat vitiligo may increase patient compliance and prove to be more significant than other commercially available oral or topical medication formulations. Methods: Clobetasol propionate-loaded niosomes were prepared by ether injection using Span 40 and Span 60 as non-ionic surfactants and Cholesterol as a stabilizing agent, and diethyl ether as a volatile organic solvent. Sunscreen was prepared using different proportions of physical and chemical UV filters to achieve optimum SPF. Results: The optimized formulation (F4) demonstrated desirable physicochemical characteristics. It had a mean particle size of 200 nm, zeta potential of -19.3 mV, and an entrapment efficiency of 84.41%, indicating appropriate vesicle size, good vesicle stability, and high drug-loading capacity. Drug release studies revealed a sustained release profile, with cumulative drug release over 12 hours of 60.69% for pure Clobetasol Propionate (CP), 70.6% for the F4 formulation, and 96.6% for the optimized (F4S2) niosomal sunscreen formulation. The release data best fit the Korsmeyer-Peppas model with an R² value of 0.9993, confirming a diffusion-controlled (Fickian) mechanism. The formulation's SPF value was found to be 18.31, significantly higher than the base cream and earlier niosomal preparations, due to the inclusion of zinc oxide and titanium dioxide. Additional evaluations, including Spreadability, pH, extrudability, and rancidity, confirmed that F4S2 is pharmaceutically acceptable for topical application in the treatment of vitiligo. Discussion: This study successfully developed and characterized a novel clobetasol propionate-loaded niosomal sunscreen (F4S2) for vitiligo management. The optimized niosomes exhibited desirable physicochemical properties, including a small particle size (200 nm) and high entrapment efficiency (84.41%), confirming their suitability as a drug delivery vehicle. The formulation demonstrated a sustained drug release profile, best described by the Korsmeyer-Peppas model, indicating controlled, anomalous diffusion. Crucially, the incorporation into a sunscreen base provided an effective SPF value, addressing the critical need for photoprotection in vitiligo patients. Overall, the F4S2 formulation offers a promising, dual-action strategy combining targeted, sustained corticosteroid delivery with essential UV protection that is expected to enhance patient compliance and therapeutic outcomes. Further in vivo studies are strongly recommended to confirm its clinical efficacy and safety. Conclusion: The in vitro characterization of clobetasol propionate-loaded niosome-based sunscreen reinforces the goal of niosome-based sunscreen as a possible vehicle for topical drug delivery of clobetasol propionate. Following rigorous evaluation in a few years, niosome-based sunscreen may also significantly improve the outcome for vitiligo skin.
No takes yet. Share an insight, caveat, or question.
Twinkle et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: